¿ Antex Biologics Incof Gaithersburg, Md., said it will provide its antigenically enhanced bacteria to O.E.M Concepts Inc., of Toms River, N.J., for the development and manufacture of proprietary antibodies for commercial use in the detection of food-borne and other enteric pathogens. O.E.M. will be responsible for the sale and distribution of these antigen affinity purified monoclonal and polyclonal antibodies to the diagnostics industry for inclusion in in vitro diagnostic kits, and Antex will receive royalties from sales.

¿ Boston Life Sciences Inc., of Boston, developed an advance in the protein manufacturing process used in production of its anti-angiogenic agent, Troponin. It said this process should yield production of highly active, pure GMP material for clinical trials and commercialization.

¿ Celera Genomics, of Rockville, Md., was awarded a grant from the National Heart, Lung and Blood Institute and the National Human Genome Research Institute to sequence the genome of the laboratory rat in collaboration with Baylor College of Medicine. The Institute for Genomic Research, of Rockville, Md., Genome Therapeutics Corp., of Waltham, Mass., and the University of British Columbia also will participate. The goal is to sequence fourfold coverage of the genome within two years.

¿ Discovery Partners International Inc., of San Diego, entered a definitive agreement to acquire Xenometrix Inc., of Boulder, Colo., through the purchase of all Xenometrix's common stock, paying 59 cents per share. Xenometrix has about 2.9 million shares outstanding, giving the estimated price of $1.7 million for the acquisition. As of Feb. 10, Xenometrix had $492,000 in cash and cash equivalents. Xenometrix has a patent portfolio for its gene profiling technology that Discovery will use in its own offering of technologies, products and services. Xenometrix will become a wholly owned subsidiary through the transaction, which has been approved by the boards of both companies but is still subject to approval by Xenometrix stockholders. Xenometrix's stock (OTCBB:XENO) moved up 12.5 cents Wednesday, or about 30 percent, to close at 53.1 cents.

¿ Dyax Corp., of Cambridge, Mass., said it signed the 50th licensee to its phage display patents. The licensee was not named. Its patented phage display technology is a high-throughput discovery platform with applications in research and development. Terms were not disclosed.

¿ Genset SA, of Paris, confirmed the departure of Bernard Bihain, vice president of physiological genomics, who is leaving to accept a position with another biotechnology company. Genset's stock (NASDAQ:GENXY) fell $3.187 Wednesday, or about 34 percent, to close at $6.125. Since the stock reached $18.375 on Jan. 19, it has been in steady decline.

¿ Genzyme Biosurgery, a division of Genzyme Corp., of Cambridge, Mass., said orthopedic surgeons reported 91 percent of patients treated with its Carticel (autologous cultured chondrocytes) to repair damaged cartilage on the thigh-bone part of the knee maintained improvement in four key measures five years after surgery. This result was reported in the summary of the seventh report of its cartilage repair registry released Wednesday during the annual meeting of the American Academy of Orthopaedic Surgeons in San Francisco.

¿ Gliatech Inc., of Cleveland, initiated work with its recently appointed independent auditor, Health Policy Associates (HPA), to identify and resolve matters of interest to the FDA related to its application integrity policy status. The FDA has communicated to HPA three initial areas of focus: the efficacy of Gliatech's product Adcon-L, the safety of Adcon-L, and manufacturing procedures and test results. Gliatech voluntarily recalled Adcon-L and Adcon-T/N worldwide, related to a recall by the supplier of a raw material component of these products. Gliatech said the work on each area could be ready for submission to the FDA in the next several months.

¿ Harvard Bioscience Inc., of Holliston, Mass., introduced ScanTox, a drug safety evaluation tool designed to reduce the number of drug candidate false positives. It is a laser-based instrument that quantifies the relative cytotoxicity of a substance within a living and functional cultured bovine lens.

¿ Illumina Inc., of San Diego, signed an agreement with Chevron Research and Technology Co., headquartered in San Francisco, to determine how BeadArray technology could be developed and applied to hydrocarbon processing operations. The study will be funded by Chevron and should complete in early 2002. They will evaluate how Illumina's fiber optic-based technology can be designed and trained to detect chemical compounds present in refining or chemical plant operations.

¿ Immusol Inc., of San Diego, entered a functional genomics collaboration for drug discovery with Chugai Pharmaceutical Co. Ltd., of Tokyo. Immusol's proprietary gene inactivation technology will be used to support Chugai's discovery and validation of drug target genes relating to cancer metastasis, to inhibit the spread of cancer. The collaboration will also target newly discovered genes from Chugai's wholly owned subsidiary, Chugai Research Institute for Molecular Medicine Inc., and Chugai's research center, Fuji Gotemba Laboratories.

¿ InterMune Pharmaceuticals Inc., of Burlingame, Calif., commenced enrollment in its Phase II trial evaluating the safety and efficacy of inhaled Actimmune (interferon gamma-1b) for the treatment of cystic fibrosis. Trial specifics were not disclosed.

¿ Isis Pharmaceuticals Inc., of Carlsbad, Calif., said its GeneTrove division extended its antisense target validation research program with Abbott Laboratories, of Abbott Park, Ill. GeneTrove uses it proprietary antisense technology to assist Abbott in determining the function and therapeutic relevance of numerous gene targets. Financial details were not disclosed.

¿ NeoPharm Inc., of Lake Forest, Ill., reached an agreement with the FDA to expand the existing cooperative research and development agreement (CRADA) to develop the anticancer agent, IL13-PE38, for the treatment of tumors that express interleukin-13 receptors. The term will now run through Dec. 31, 2003. NeoPharm is conducting Phase I trials of IL13-PE38 and systemic and intratumoral administration and has increased the scope of the CRADA.

¿ Pharmagene plc, of Royston, England, signed a drug discovery agreement with Bayer plc, a unit of Bayer AG, of Leverkusen, Germany. Bayer will use Pharmagene's knowledge in human tissue for the generation of a dataset to aid the validation of potential drug targets identified by Bayer.

¿ PPD Inc., of Wilmington, N.C., said its wholly owned subsidiary, PPD Discovery, has a technology access agreement with InforMax Inc., of Rockville, Md., to use the GenoMax enterprise bioinformatics system. PPD Discovery will gain broad access to the system to manage and analyze genomic data resulting from PPD's functional genomics research program.

¿ Rosetta Inpharmatics Inc., of Kirkland, Wash., said GeneticXchange Inc., of Menlo Park, Calif., InforMax Inc., of Rockville, Md., and NetGenics Inc., of Cleveland, joined the GEML Community. The GEML (Gene Expression Markup Language) Community was established as a forum for members to exchange ideas regarding the future of gene expression data interchange, and to participate in the ongoing development of the GEML format.